Daiichi Sankyo Company, Limited: HERTHENA-Lung01 Phase 2 Study of Daiichi Sankyo's Patritumab Deruxtecan Initiated in Patients with EGFR-Mutated NSCLC
(1) Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that the first patient has been dosed in HERTHENA-Lung01, a phase 2 study evaluating patritumab deruxtecan, a HER3 directed DXd antibody drug conjugate (ADC), in patients with epidermal growth factor receptor (EGFR)-mutated metastatic or locally advanced non-small cell lung cancer (NSCLC) previously treated with a tyrosine kinase inhibitor (TKI) and platinum-based chemotherapy. Lung cancer is the leading cause of ca...
United States Masashi Kawase Patritumab Deruxtecan Daiichi Sankyo Daiichi Sankyo Europe Gmb Jennifer Brennan
Source: finanznachrichten.de